Best in Biotech 16 Feb 2022 Top 10 Biotech Companies in Stevenage, UK’s Hidden Life Sciences Gem These are the top biotech companies based in Stevenage, an English town that has become a life sciences hub that competes with the likes of London, Oxford, and Cambridge. The UK’s life sciences scene is mostly centered around the golden triangle of London, Oxford, and Cambridge. Situated right in the middle of this triangle, the […] February 16, 2022 - 6 minutesmins - By Clara Rodríguez Fernández Share WhatsApp Twitter Linkedin Email
News and Trends 17 Dec 2020 Covid-19 Leaves Lasting Impact on Hematology at ASH 2020 Conference Under the heavy shadow of the Covid-19 pandemic, last week’s annual conference of the American Society of Hematology (ASH) displayed the achievements of many innovative treatments for blood conditions, including gene and cell therapies. A sweeping new wave of Covid-19 infections that is forcing new lockdowns across the northern hemisphere is already reshaping the biotech […] December 17, 2020 - 6 minutesmins - By Victor Kotsev Share WhatsApp Twitter Linkedin Email
News and Trends 9 Dec 2019 Autolus Reveals Early Clinical Data of Next-Gen CAR-T Therapy London-based Autolus has shown its next-generation CAR T-cell therapy does not induce some of the severe side effects that have led to deaths in patients treated with CAR T-cell treatments currently on the market. Since their arrival on the market in 2017, CAR T-cell therapies have provided hope to patients with rare forms of blood […] December 9, 2019 - 4 minutesmins - By Clara Rodríguez Fernández Share WhatsApp Twitter Linkedin Email
News and Trends 12 Aug 2019 Manufacturing Delays Set Back Autolus’ CAR-T Programs by Five Months The UK biotech Autolus’ shares have slumped as construction delays from a new manufacturing site have pushed back its CAR-T cell immunotherapy programs. Autolus is developing treatments for blood cancer that involve engineering patients’ own immune cells to kill cancer cells, known as autologous CAR-T cell immunotherapies. Earlier this year, Autolus licensed a new manufacturing […] August 12, 2019 - 2 minutesmins - By Jonathan Smith Share WhatsApp Twitter Linkedin Email
News and Trends 22 Jun 2018 Next-Generation CAR-T Company Raises €130M on NASDAQ IPO London-based Autolus has made its debut on the NASDAQ raising funds to boost the development of a next generation of CAR-T cell therapy for cancer. Founded in 2014 as a spin-out from University College London, Autolus has been taking great strides to develop its CAR-T technology. In less than four years, the company managed to raise nearly €150M […] June 22, 2018 - 2 minutesmins - By Clara Rodríguez Fernández Share WhatsApp Twitter Linkedin Email
News and Trends 14 Nov 2017 This British Biotech Could Treat T-Cell Lymphoma without Leaving the Body Unprotected Autolus has revealed a new strategy to treat T-cell lymphoma without harming healthy, protective T cells. The therapy is expected to start human tests soon. T-cell lymphoma is a form of cancer that affects the cells responsible for protecting our body against infections. Unlike it’s done with cancer types that affect other blood cells, it’s […] November 14, 2017 - 2 minutesmins - By Clara Rodríguez Fernández Share WhatsApp Twitter Linkedin Email
News and Trends 26 Sep 2017 British Biotech Pockets Massive Series C for its CAR-T Cancer Therapies Autolus, based in London, has raised €68M in Series C to continue developing its T cell immunotherapies for cancer treatment. Autolus focuses on developing engineered T cell immunotherapies to beat cancer. Its pipeline includes therapies targeted at both hematological cancers and solid tumors. The Series C fundraising of $80M (€68M) is added to £70M (€80M) made in Series A […] September 26, 2017 - 3 minutesmins - By Alex Dale Share WhatsApp Twitter Linkedin Email